Condition: Pregnant Individuals · Aneuploidy · Down Syndrome (Trisomy 21) · Sponsor: BillionToOne Inc.
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.
This description comes directly from the study's public registry record.
Shannon O'Rourke Senior Research Manager, MS, CGC · 650-460-2551 · unityregistry@billiontoone.com
Always discuss trial participation with your own doctor first.
| Valley Perinatal Services | Phoenix, Arizona, United States | Recruiting |
| San Gabriel Valley Perinatal Medical Group | West Covina, California, United States | Recruiting |
| Sarasota Memorial Health Care System | Sarasota, Florida, United States | Recruiting |
| Pediatrix Medical Group of Georgia | Atlanta, Georgia, United States | Recruiting |
| Woman's Hospital | Baton Rouge, Louisiana, United States | Recruiting |
| Pediatrix Medical Group | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07643896